破裂腹主动脉瘤EVAR中局部麻醉较全身麻醉降低死亡率:VQI数据库分析
基于VQI数据库2003-2017年3330例破裂腹主动脉瘤患者,比较局部麻醉与全身麻醉下EVAR的预后。
要点
- 破裂腹主动脉瘤EVAR中局部麻醉较全身麻醉降低30天和1年死亡率。
- 局部麻醉组术中时间、输血、晶体液、ICU时间和肺部并发症均减少。
- 年龄<75岁且无术前低血压者从局部麻醉中生存获益最大。
核心结论
- 破裂腹主动脉瘤EVAR中局部麻醉可能是特定患者的安全选择,发病率更低且死亡率改善。
- 需进一步前瞻性研究证实局部麻醉的生存获益。
研究设计与样本
- 回顾性队列研究,查询Vascular Quality Initiative数据库2003-2017年破裂腹主动脉瘤患者。
- 共纳入3330例患者(77.4%男性),其中开放修复1594例(47.9%),局部麻醉EVAR 226例(6.8%),全身麻醉EVAR 1510例(45.3%)。
- 观察终点为死亡或1年随访,采用Kaplan-Meier法计算30天和1年事件率,Cox比例风险回归模型调整人口学和临床因素。
主要发现
- 局部麻醉EVAR组较全身麻醉EVAR组术中时间、术中输血量、术中晶体液输入量、ICU住院时间和术后肺部并发症均减少。
- 年龄<75岁且无术前低血压者从局部麻醉中生存获益最大(双因素:AHR 0.14,95%CI 0.03-0.57;单因素:AHR 0.57,95%CI 0.36-0.91)。
临床怎么用
- 对于破裂腹主动脉瘤行EVAR的特定患者,局部麻醉可作为全身麻醉的替代方案以降低死亡率和并发症。
- 年龄<75岁且无术前低血压的患者可能从局部麻醉中获益最大。
局限性
- 回顾性数据库研究,可能存在选择偏倚和未测量混杂因素。
- 局部麻醉组样本量较小(226例)。
- 需要前瞻性研究证实生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular aneurysm repair (EVAR) is an accepted approach for patients presenting with ruptured abdominal aortic aneurysm (rAAA) and suitable anatomy. The effect of anesthesia modality on mortality outcomes in rAAA has not been well described. Using the Vascular Quality Initiative database, this study compares local anesthesia (LA) vs general anesthesia (GA) in EVAR for rAAA. METHODS: The Vascular Quality Initiative database was queried for patients presenting with rAAA managed with open surgical repair, EVAR under LA (rEVAR-LA), and EVAR under GA (rEVAR-GA) between 2003 and 2017. Patients were observed until the earlier end point of either death or 1-year follow-up. Kaplan-Meier event rates are presented at 30 days and 1 year. Cox proportional hazards regression was used to model risk of death, with adjustment for demographic and clinical factors. Additional multivariate Cox hazards analyses were used to assess effect modifiers for 1-year mortality for the different repair methods. RESULTS: A total of 3330 patients (77.4% male) met the inclusion criteria (1594 [47.9%] open surgical repair, 226 [6.8%] rEVAR-LA, and 1510 [45.3%] rEVAR-GA). Patients treated with rEVAR-LA compared with rEVAR-GA had decreased intraoperative time, number of intraoperative blood transfusions, intraoperative crystalloid administration, intensive care unit length of stay, and postoperative pulmonary complications. Mortality rates with rEVAR-LA were lower compared with rEVAR-GA at 30 days (15.5% vs 23.3%; adjusted hazard ratio [AHR], 0.70; 95% confidence interval [CI], 0.49-0.99; P = .04) and at 1 year (22.5% vs 32.3%; AHR, 0.71; 95% CI, 0.53-0.96; P = .02). Patients undergoing EVAR who were <75 years old and those without preoperative hypotension had the greatest survival benefit from LA compared with GA (both factors: AHR, 0.14 [95% CI, 0.03-0.57]; single factor: AHR, 0.57 [95% CI, 0.36-0.91]). CONCLUSIONS: This study demonstrates that rEVAR-LA for rAAA may be a safe alternative to rEVAR-GA for certain patients, with lower morbidity and improved mortality. Further prospective study is warranted to confirm mortality benefit in rEVAR-LA for rAAA.
引用
- Faizer R, Weinhandl E, El Hag S, et al. Decreased mortality with local versus general anesthesia in endovascular aneurysm repair for ruptured abdominal aortic aneurysm in the Vascular Quality Initiative database. J Vasc Surg. 2019. PMID: 30611580. doi:10.1016/j.jvs.2018.10.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。